NDAORALTABLET
Approved
Apr 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCODAN is an oral tablet combining aspirin with oxycodone hydrochloride, a Schedule II opioid analgesic indicated for moderate to severe pain management. This fixed-dose combination leverages the anti-inflammatory properties of aspirin with the potent analgesic effects of oxycodone to provide multimodal pain relief.
LOE Approaching
As LOE approaches and competitive pressure remains moderate (30%), commercial teams should expect declining market share and reduced headcount allocation to this legacy franchise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PERCODAN as it approaches LOE offers limited growth opportunity but stable work in managed market transitions, generic parity strategy, and regulatory compliance. This role suits professionals seeking to consolidate expertise in legacy products or transition toward portfolio management in post-LOE phases rather than pursuing high-growth launch or expansion careers.
Brand Manager
Worked on PERCODAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.